Observational study on kidney transplant rejection predictors in Scotland
Official title: KTRSensor Scotland Study: Investigating the Role of Biomarkers in Kidney Transplant Outcomes
Run by University of Edinburgh · NCT06830473 · Data updated 2026-11-12
This study looks at kidney transplant patients in Scotland to see if certain markers in their urine can help predict if their new kidney might be rejected.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University of Edinburgh Academic / other |
| Locations | 2 sites (Edinburgh and 1 other locations) |
| Status | Recruiting |
| Started | May 16, 2025 |
| Main results expected | May 13, 2028 |
| Study ends | May 13, 2028 |
| Registry record updated | February 10, 2026 |
| Trial ID | NCT06830473 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients who have undergone a kidney transplant at a Scottish transplant center and are attending routine follow-up appointments.
✕Probably not a fit
Patients who have not previously undergone a kidney transplant or those attending follow-up at peripheral sites may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to capture real-world data from kidney transplant patients in Scotland to identify clinical biomarkers in urine that may predict early graft rejection. By following patients during their routine post-operative follow-up appointments, the study seeks to improve understanding of kidney transplant outcomes. The primary focus is on assessing the presence of specific biomarkers that could indicate the likelihood of transplant rejection, thereby enhancing patient management and care.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of kidney transplant patients, potentially reducing the incidence of graft rejection.
How similar studies have gone: While the approach of using biomarkers to predict transplant rejection is established, this specific observational study may provide novel insights into real-world applications and outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Any patient within a Scottish Transplant centre who has undergone renal transplant (+/- pancreas/islet) and is due to attend routine follow-up appointments at the index centre. Exclusion criteria: * no previous kidney transplant * patient attending follow-up at a peripheral site * unable to provide urine samples across the study duration
Where it's running
-
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom Recruiting -
Queen Elizabeth University Hospital
Glasgow, United Kingdom Recruiting
Study contacts
- Study coordinator: Alexander J Le Saint-Grant, MBChB
- Email: Lex.LeSaint-Grant@ed.ac.uk
- Phone: +44 131 651 8100
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)
This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.
-
How Propofol and Sevoflurane Affect miRNA in Living Kidney Donors
This study tests whether using propofol or sevoflurane during donor nephrectomy changes levels of miRNAs in living kidney donors.
-
Effects of general vs spinal-epidural anesthesia on kidney transplant biomarkers
This study tests whether sevoflurane general anesthesia or combined spinal-epidural anesthesia changes markers of cellular stress and protective peptides in adults undergoing kidney transplantation.
-
How kidney transplant patients feel about using artificial intelligence in medicine
This international survey asks adults who have had a kidney transplant how they feel about AI tools that predict graft loss and what it might mean for their daily care.
-
AdiaVita regenerative therapy for chronic kidney disease
This trial tests whether AdiaVita (umbilical cord blood stem cells and exosomes plus glutathione) can improve kidney function in adults with stage 2–4 chronic kidney disease.
-
Personalized therapeutic stories for children after kidney transplant.
We will test whether clinician-supervised AI can create age-appropriate, personalized therapeutic stories for children aged 5–12 who have received a kidney transplant and their families.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.